YOLFTbeta
Editas Medicine Inc

Editas Medicine Inc

EDIT · NASDAQ · Healthcare / Biotechnology

2.17USD+0.03 (+1.40%)

Price History

Full chart

Market Stats

Previous Close2.14
Open2.14
Day Range2.01 – 2.21
52-Week Range1.66 – 4.54
Volume2.79M
Market Cap422.35M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.68
Dividend Yield0.00%
Beta2.09
50-Day Avg2.87
200-Day Avg2.64

About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Gilmore O'Neill M.D.
  • Employees87
  • Headquarters11 Hurley Street, Cambridge, MA, United States, 02141, USA
  • Websitehttps://www.editasmedicine.com

Leadership

  • Dr. Gilmore O'Neill M.D.President, CEO & Director · b. 1964
  • Ms. Amy ParisonSenior VP & CFO · b. 1986
  • Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific Officer · b. 1957
  • Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board Member · b. 1954
  • Mr. Gregory WhiteheadExecutive VP and Chief Technical & Quality Officer
  • Mr. Damien Grierson J.D.Senior VP, General Counsel & Corporate Secretary
  • Mr. Tom LoveVice President of People
  • Mr. Frank PanaccioSenior VP & Chief Business Officer
  • Ms. Brieana BuckleySenior Vice President of Development and Program Leadership

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-01.63M6.05M13.73M31.94M20.53M90.73M25.54M19.71M78.12M32.31M40.52M
Growth (%)---+271.58%+126.80%+132.64%-35.71%+341.93%-71.85%-22.83%+296.32%-58.64%+25.39%
Cost of Revenue1.59M5.07M18.85M56.98M83.16M90.65M96.90M158.00M5.05M6.34M6.06M199.25M5.28M
Gross Profit-1.59M-5.07M-17.22M-50.93M-69.43M-58.72M-76.37M90.73M25.54M19.71M72.06M-166.93M40.52M
Gross Margin---1056.91%-841.33%-505.76%-183.85%-371.96%100.00%100.00%100.00%92.24%-516.60%100.00%
Operating Expense3.63M7.65M18.09M46.26M50.50M55.01M64.56M225.57M218.69M245.66M241.24M84.22M139.86M
Operating Income-5.22M-12.72M-35.31M-97.19M-119.93M-113.73M-140.92M-134.84M-193.15M-225.95M-169.18M-251.15M-99.34M
Operating Margin---2167.71%-1605.62%-873.64%-356.10%-686.39%-148.61%-756.13%-1146.26%-216.56%-777.22%-245.15%
EBITDA-5.22M-13.49M-72.29M-96.07M-116.66M-110.47M-138.09M-130.88M-188.09M-219.61M-147.16M-233.11M-148.61M
EBITDA Margin---4437.45%-1587.11%-849.82%-345.91%-672.60%-144.25%-736.35%-1114.11%-188.36%-721.39%-366.76%
Net Income-5.35M-13.69M-72.90M-97.18M-120.32M-109.95M-133.75M-109.41M-185.11M-204.35M-153.22M-237.09M-160.06M
Net Income Margin---4475.14%-1605.53%-876.49%-344.28%-651.43%-120.59%-724.66%-1036.69%-196.13%-733.72%-395.01%
R&D1.59M5.07M18.85M56.98M83.16M90.65M96.90M158.00M142.51M174.96M177.65M199.25M89.95M
R&D as % of Total Revenue--1156.91%941.33%605.76%283.85%471.96%174.13%557.89%887.57%227.40%616.60%222.00%
Interest Expense-34.00K143.00K62.00K978.00K3.44M7.31M2.60M5.70M4.22M-2.19M6.17M
Interest Expense % of Total Revenue--8.78%1.02%7.12%10.79%35.62%2.87%22.30%21.43%-6.78%15.23%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.48M12.19M149.36M229.18M373.26M420.39M508.88M572.60M677.48M514.32M499.15M341.59M186.53M
Total Liabilities4.24M27.48M232.48M94.58M165.18M184.22M246.45M179.02M123.84M153.64M150.06M207.31M159.25M
Total Equity-1.76M-15.29M-83.11M134.61M208.08M236.16M262.44M393.59M553.64M360.68M349.10M134.27M27.29M
Cash2.01M10.62M143.18M185.32M146.63M134.78M238.18M139.68M203.52M141.52M123.65M131.54M146.65M
Total Debt2.11M411.00K199.91M45.10M40.93M45.23M29.08M26.14M26.38M43.95M48.54M35.03M76.71M
Net Debt99.00K-10.21M56.73M-150.23M-113.20M-102.36M-209.10M-113.55M-177.14M-97.58M-75.11M-96.51M-69.94M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.78M-8.65M-5.40M-49.93M-9.42M-45.71M-40.67M-179.84M-163.80M-177.35M-132.18M-210.28M-165.24M
Investing Cash Flow-159.00K-1.22M-1.43M-5.09M-183.81M-53.09M12.25M-140.52M-54.47M114.07M-3.73M162.15M138.67M
Financing Cash Flow8.98M18.48M139.39M97.16M154.53M86.94M131.82M224.12M282.11M1.28M118.04M56.03M40.47M
Capital Expenditure159.00K1.22M1.43M3.49M2.06M4.75M6.17M7.16M7.98M4.12M4.72M8.83M607.00K
Free Cash Flow-2.94M-9.87M-6.83M-53.42M-11.48M-50.46M-46.84M-187.00M-171.78M-181.47M-136.90M-219.11M-165.85M
Dividends Paid--143.19M782.00K11.00K4.00K-------
FCF to OCF105.71%114.06%126.49%107.00%121.86%110.40%115.16%103.98%104.87%102.32%103.57%104.20%100.37%
Dividend Paid to FCF---2095.32%-1.46%-0.10%-0.01%-------

Earnings

Report DateMar 30, 2016May 13, 2016Aug 9, 2016Nov 7, 2016Mar 3, 2017May 15, 2017Aug 9, 2017Nov 7, 2017Mar 6, 2018May 3, 2018Aug 6, 2018Nov 7, 2018Feb 28, 2019May 7, 2019Aug 6, 2019Nov 12, 2019Feb 26, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Feb 25, 2021May 5, 2021Aug 4, 2021Nov 8, 2021Feb 24, 2022May 4, 2022Aug 3, 2022Nov 2, 2022Feb 22, 2023May 5, 2023Aug 2, 2023Nov 3, 2023Feb 28, 2024May 8, 2024Aug 7, 2024Nov 4, 2024Feb 26, 2025May 12, 2025Aug 12, 2025Nov 10, 2025Feb 19, 2026May 5, 2026Aug 5, 2026Nov 9, 2026
EPS Estimate-0.52-0.32-0.56-0.64-0.62-0.77-0.57-0.63-0.78-0.80-0.66-0.81-0.32-0.64-0.62-0.730.06-0.79-0.82-0.63-0.74-0.71-0.81-0.81-0.72-0.79-0.80-0.85-0.81-0.78-0.77-0.58-0.54-0.64-0.71-0.77-0.33-0.59-0.38-0.38-0.23-0.24-0.30-0.21
EPS Actual-4.05-0.80-0.54-0.59-1.10-0.85-0.65-0.64-0.84-0.67-0.82-0.32-0.52-0.60-0.69-0.66-0.74-0.69-0.430.12-1.00-0.86-0.81-0.57-0.61-0.74-0.78-0.81-0.88-0.71-0.56-0.55-0.23-0.76-0.82-0.75-0.55-0.92-0.32-0.28-0.06-0.26-0.15-
Surprise-678.85%-150.00%3.57%7.81%-77.42%-10.39%-14.04%-1.59%-7.69%16.25%-24.24%60.49%-62.50%6.25%-11.29%9.59%-1333.33%12.66%47.56%119.05%-35.14%-21.13%0.00%29.63%15.28%6.33%2.50%4.71%-8.64%8.97%27.27%5.17%57.41%-18.75%-15.49%2.60%-67.38%-55.93%15.79%26.32%73.94%-8.33%50.00%-
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-market-Pre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap422.35M
Enterprise Value213.92M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales8.99
Price / Book3.89
EPS-0.68
Book Value0.686
Revenue (TTM)47.01M
Gross Profit (TTM)-37.95M
EBITDA-81.03M
Profit Margin-157.32%
Operating Margin-167.31%
Return on Equity-118.82%
Return on Assets-23.29%
Shares Outstanding153.58M
Shares Float115.49M
Beta2.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 15 analystsTarget 5.90
  • Strong Buy
    4
  • Buy
    1
  • Hold
    8
  • Sell
    2

Ownership Breakdown

Institutions
79.29%
Insiders
0.18%
Retail / Other
20.53%

Top Institutional Holders

  • TCG Crossover Management, LLC
    11.11M7.23%
  • BlackRock Inc
    9.26M6.03%
  • Paradigm Biocapital Advisors LP
    5.59M3.64%
  • Vanguard Capital Management, LLC
    4.20M2.74%
  • Renaissance Technologies Corp
    3.97M2.59%
  • Opaleye Management Inc
    3.86M2.51%
  • Vivo Capital, LLC
    3.56M2.31%
  • Vanguard Portfolio Management, LLC
    3.15M2.05%
  • GordonMD Global Investments LP
    3.13M2.04%
  • Geode Capital Management, LLC
    2.31M1.51%
  • Logos Global Management LP
    2.22M1.45%
  • State Street Corp
    2.08M1.35%
  • Nuveen, LLC
    1.98M1.29%
  • JPMorgan Chase & Co
    1.95M1.27%
  • D. E. Shaw & Co LP
    1.90M1.24%
  • Acadian Asset Management LLC
    1.46M0.95%
  • AQR Capital Management LLC
    1.37M0.89%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.89M3.18%
  • iShares Russell 2000 ETF
    2.60M1.69%
  • Vanguard Strategic Equity Inv
    2.03M1.32%